ETF Research Center

The Global X Genomics & Biotechnology ETF seeks to track the performance, before fees and expense, of the Solactive Genomics Index.

FUND BASICS
Category	US Equities
Fund Sponsor	Global X
Website	www.globalxfunds.com
Inception date	Apr 08, 2019
Assets (mns)	$1
Currency	USD
Expense ratio	68 bp
Distributions	Quarterly

FUND STRUCTURE
Regulation	Open-Ended Fund
Custodian
Weighting
Index replication
Uses derivatives	No
Options available	No

SECTOR BREAKDOWN

CONSTITUENT BREAKDOWN
No. of constituents	40
Wgt avg mkt cap (mns)	$11,494
Large cap (>$10bn)	21.3%
Mid cap ($2-10bn)	43.7%
Small cap (<$2bn)	35.0%
Developed mkts	100.0%
Emerging mkts	0.0%

TOP TEN HOLDINGS
Total	46.0 %
ARROWHEAD PHARMACEUTICALS, INC.	7.0 %
GENSCRIPT BIOTECH CORPORATION	4.8 %
PTC THERAPEUTICS INC	4.8 %
ALNYLAM PHARMACEUTICALS INC	4.6 %
VERTEX PHARMACEUTICALS INC	4.6 %
SPARK THERAPEUTICS, INC.	4.2 %
ILLUMINA INC	4.1 %
AGILENT TECHNOLOGIES INC	4.1 %
BLUEPRINT MEDICINES CORP.	3.9 %
NATERA INC	3.9 %

TOP COUNTRY EXPOSURE
	UNITED STATES	85.2 %
	NETHERLANDS	6.3 %
	CHINA	4.9 %
	SWITZERLAND	2.9 %
	SINGAPORE	1.6 %

HISTORICAL PERFORMANCE info

	Custom date range	Compare to
	thru

Standardized Annual Returns (thru October 31)
Year-to-date	1 year	5 years	10 years	Since Incep.
-7.9%	--	--	--	-7.9%

Market Correlations
versus...	Beta	R-squared
S&P500	--	--
MSCI EAFE	--	--
MSCI Emg. Mkts.	--	--

Technical Indicators
Recent close	$13.80
30d moving avg.	$12.98
Annualized volatility	0.0%
Short interest (ETF)	0.0%
Relative strength (RSI)	70

Liquidity measures
Avg. volume (thou.)	2
Turnover	2.0%
Bid/Ask (% of price)	0.24%
ADV underlying (mns)	$2,575

Distributions

FINDING ALTERNATIVE FUNDS

Below is a list of 20 potential alternatives to the Global X Genomics & Biotechnology ETF based on the alternatives' overlap in portfolio holdings with GNOM. Consider funds with lower expense ratios and/or higher ALTAR Score™ ratings as possible alternatives.

Benchmark ticker:

GNOM

Expense:

68 bp

ALTAR Score™:

-6.4%

ALTERNATIVE ETFs BASED ON OVERLAP WITH GNOM
Ticker	Fund Name	Overlap¹ vs GNOM (%)	Expense ratio (bp)	Savings vs GNOM (bp)	ALTAR Score™ (%)	ALTAR vs GNOM (%)
XBI	SPDR S&P Biotech ETF	28.0	35	33	-5.1	+1.4
FBT	First Trust NYSE-ARCA Biotechnology	26.9	57	11	-0.8	+5.6
BBH	VanEck Vectors Biotech	26.3	35	33	5.4	+11.9
IDNA	iShares Genomics Immunology and Healthcare	24.1	47	21	-4.8	+1.6
IBB	iShares NASDAQ Biotechnology	23.2	47	21	1.3	+7.7
PBE	Invesco Dynamic Biotechnology & Genome	20.0	57	11	0.0	+6.5
BTEC	Principal Healthcare Innovators Index	19.0	42	26	-4.6	+1.8
BBP	BioShares Biotech Products	16.7	79	-11	-3.9	+2.5
ARKG	ARK Genomic Revolution Multi-Sector	15.2	75	-7	-4.2	+2.2
HTEC	Robo Global Healthcare Technology and Innovation	14.7	68	0	0.0	+6.4
IEIH	iShares Evolved U.S. Innovative Healthcare	14.6	18	50	4.9	+11.3
BBC	Virtus LifeSci Biotech Clinical Trials	14.3	79	-11	-14.4	-8.0
ARKK	ARK Innovation	14.1	75	-7	-4.8	+1.6
GDNA	Goldman Sachs Motif Human Evolution	11.4	50	18	1.0	+7.4
CNCR	Loncar Cancer Immunotherapy	8.7	79	-11	-3.9	+2.6
FHLC	Fidelity MSCI Health Care	8.3	8	60	6.1	+12.5
IYH	iShares US Healthcare	8.3	43	25	6.6	+13.0
RYH	Invesco S&P Equal Weight Healthcare	8.2	40	28	7.3	+13.7
QQXT	First Trust NASDAQ-100 Ex-Tech	8.2	60	8	6.1	+12.5
VHT	Vanguard Health Care	8.1	10	58	6.1	+12.5

¹Overlap is the percentage of holdings by weight that are identical. For example, if Fund A has a 2% position in Apple, Inc. (AAPL) and Fund B has a 5% position, their overlapping position in AAPL is 2%.

Content on this tab for subscribers only**

RESULTS & ESTIMATES

	2014	2015	2016	2017	2018	2019E	2020E
Sales per share	**	**	**	**	**	**	**
Earnings per share	**	**	**	**	**	**	**
Dividends per share	**	**	**	**	**	**	**
Book value per share	**	**	**	**	**	**	**

Sales per share growth		**%	**%	**%	**%	**%	**%
EPS growth		**%	**%	**%	**%	**%	**%

Sales per share growth		**%	**%	**%	**%	**%	**%
EPS growth		**%	**%	**%	**%	**%	**%

OTHER FUNDAMENTAL METRICS

Long term EPS growth est.	**%		Debt-to-equity	**x
Asset turnover	**%		Assets-to-equity	**x

Return on equity

Revision activity*

*Six months ago = 100

Net margins

Compound annual growth rates

Content on this tab for subscribers only

VALUATION METRICS

	2018	2019E	2020E
Price-to-sales	**	**	**
Price-to-earnings	**	**	**
Price-to-cash flow	**	**	**
Price-to-growth	**	**	**
Price-to-book value	**	**	**
Yield	**	**	**

Historical valuation trends

Forward multiple:	Global X Genomics & Biotechnology
Relative to:	S&P500	MSCI EAFE	MSCI Emg. Mkts.	Other ETF:

AVOID

Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant.

ALTAR Score™

Calculation of ALTAR Score™
Avg. Return on Equity	-39.8	%
Divided by: Fwd. P/BV	6.9	x
Less: Expense ratio	68	bp
Equals: ALTAR Score	-6.4	%

More information on ALTAR Score™

MODERN PORTFOLIO THEORY info

CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS

COMPOSITE RATING	1.40	CATEGORY AVERAGE	1.55

The composite rating is a weighted average of analysts' consensus recommendations for individual ETF constituents, based on the following scale: BUY = 1; OVERWEIGHT = 1.5, HOLD = 2; UNDERWEIGHT = 2.5; and SELL = 3. Readers are cautioned that because analyst ratings tend to be inflated, the composite score may be more useful as a relative measure of sentiment between funds rather than as a stand-alone recommendation.